Wall Street analyst price targets, ratings consensus & upside potential
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Spero Therapeutics, Inc. (SPRO) has a Wall Street consensus price target of N/A, based on estimates from 13 covering analysts. The company has a market capitalization of $122M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, SPRO trades at a trailing P/E of -1.7x and forward P/E of 3.2x. Analysts expect EPS to grow +186.0% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SPRO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus price target for SPRO is $N/A, close to the current price of $2.17 (N/A% implied move). Based on 13 analyst estimates, the stock appears fairly valued near current levels.
SPRO has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
With a forward P/E of 3.2388x, SPRO trades at a relatively low valuation. The consensus target of $N/A implies N/A% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $N/A for SPRO, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
SPRO is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 5 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SPRO stock forecast based on 13 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
SPRO trades at a forward P/E ratio of 3.2x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
SPRO appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SPRO analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.